Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination
Authors:ID Janžič, Urška, Klinika Golnik, Medicinska fakulteta UL (Author)
ID Bidovec, Urška, Klinika Golnik (Author)
ID Mohorčič, Katja, Klinika Golnik (Author)
ID Mrak, Loredana, Klinika Golnik (Author)
ID Fokter Dovnik, Nina (Author)
ID Ivanović, Marija (Author)
ID Ravnik, Maja (Author)
ID Čakš, Marina (Author)
ID Škof, Erik (Author)
ID Debeljak, Jerneja, Klinika Golnik (Author)
ID Korošec, Peter, Klinika Golnik, Fakulteta za farmacijo UL (Author)
ID Rijavec, Matija, Klinika Golnik, Biotehniška fakulteta UL (Author)
Files:.pdf PDF - Presentation file, download (2,03 MB)
MD5: CA4038977033DC2EEB666EA80845FD83
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and second doses and 3 months after a complete primary course of vaccination. Results were compared with healthy controls. Results: Of 112 patients, the seroconversion rate was 96%. A significant reduction in antibody levels was observed 3 months after vaccination in patients receiving immune checkpoint inhibitors versus control participants (p < 0.001). Adverse events were mostly mild. Conclusion: Immunogenicity after mRNA-based vaccine in cancer patients is adequate but influenced by the type of anticancer therapy. Antibody levels decline after 3 months, and thus a third vaccination is warranted.
Keywords:onkološko zdravljenje, imunogenost, osnovno cepljenje mRNA, čvrsti tumorji, anticancer treatment, immunogenicity, mRNA-based vaccination, solid cancer
Year of publishing:2022
Publication status in journal:In print
Article version:Postprint, final article version, accepted into publication
Publisher:Future Medicine
Number of pages:str. [1-10]
Numbering:Vol. , iss.
Source:Velika Britanija
PID:20.500.12556/DiRROS-15227 New window
UDC:616-006
ISSN on article:1479-6694
DOI:10.2217/fon-2022-0148 New window
COBISS.SI-ID:111378179 New window
Copyright:(C) 2022 The Authors
Note:Soavtorji: Urška Bidovec-Stojković, Katja Mohorčič, Loredana Mrak, Nina Fokter Dovnik, Marija Ivanović, Maja Ravnik, Marina Čaks, Erik Škof, Jerneja Debeljak, Peter Korošec & Matija Rijavec;
Publication date in DiRROS:24.06.2022
Views:342
Downloads:118
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Share:AddThis
AddThis uses cookies that require your consent. Edit consent...

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Future oncology
Publisher:Future Medicine Ltd.
ISSN:1479-6694
COBISS.SI-ID:513902617 New window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:09.06.2022

Back